AU2011300818B2 - SDF-1 binding nucleic acids and the use thereof in cancer treatment - Google Patents

SDF-1 binding nucleic acids and the use thereof in cancer treatment Download PDF

Info

Publication number
AU2011300818B2
AU2011300818B2 AU2011300818A AU2011300818A AU2011300818B2 AU 2011300818 B2 AU2011300818 B2 AU 2011300818B2 AU 2011300818 A AU2011300818 A AU 2011300818A AU 2011300818 A AU2011300818 A AU 2011300818A AU 2011300818 B2 AU2011300818 B2 AU 2011300818B2
Authority
AU
Australia
Prior art keywords
nucleic acid
sdf
acid molecule
seq
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011300818A
Other languages
English (en)
Other versions
AU2011300818A1 (en
Inventor
Klaus Buchner
Nicole Dinse
Dirk Eulberg
Florian Jarosch
Sven Klussmann
Christian Maasch
Werner Purschke
Dirk Zboralski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TME Pharma AG
Original Assignee
TME Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TME Pharma AG filed Critical TME Pharma AG
Publication of AU2011300818A1 publication Critical patent/AU2011300818A1/en
Application granted granted Critical
Publication of AU2011300818B2 publication Critical patent/AU2011300818B2/en
Assigned to TME Pharma AG reassignment TME Pharma AG Request to Amend Deed and Register Assignors: NOXXON PHARMA AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011300818A 2010-09-09 2011-09-09 SDF-1 binding nucleic acids and the use thereof in cancer treatment Active AU2011300818B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10009397 2010-09-09
EP10009397.0 2010-09-09
PCT/EP2011/004554 WO2012031773A1 (en) 2010-09-09 2011-09-09 Sdf-1 binding nucleic acids and the use thereof in cancer treatment

Publications (2)

Publication Number Publication Date
AU2011300818A1 AU2011300818A1 (en) 2013-03-07
AU2011300818B2 true AU2011300818B2 (en) 2015-11-12

Family

ID=44653255

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011300818A Active AU2011300818B2 (en) 2010-09-09 2011-09-09 SDF-1 binding nucleic acids and the use thereof in cancer treatment

Country Status (14)

Country Link
US (3) US20130310442A1 (enExample)
EP (1) EP2613789B1 (enExample)
JP (1) JP6243736B2 (enExample)
KR (1) KR101937939B1 (enExample)
CN (1) CN103108641B (enExample)
AU (1) AU2011300818B2 (enExample)
BR (1) BR112013005664B8 (enExample)
CA (1) CA2810950C (enExample)
DK (1) DK2613789T3 (enExample)
ES (1) ES2678497T3 (enExample)
MX (1) MX357770B (enExample)
RU (1) RU2679495C2 (enExample)
SG (2) SG188220A1 (enExample)
WO (1) WO2012031773A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG188220A1 (en) * 2010-09-09 2013-04-30 Noxxon Pharma Ag Sdf-1 binding nucleic acids and the use thereof in cancer treatment
WO2017178119A1 (en) * 2016-04-15 2017-10-19 Noxxon Pharma Ag Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
EP4173639A4 (en) 2020-06-26 2024-03-13 RaQualia Pharma Inc. METHOD FOR SELECTING A CANCER PATIENT FOR WHICH COMBINATION THERAPY OF A RETINOID AND A CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINATION DRUG OF A RETINOID AND A CANCER TREATMENT AGENT

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008009437A2 (en) * 2006-07-18 2008-01-24 Noxxon Pharma Ag Sdf-i binding nucleic acids
WO2009019007A2 (en) * 2007-08-06 2009-02-12 Noxxon Pharma Ag Sdf-1 binding nucleic acids and the use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
DE69932510T2 (de) 1998-03-24 2007-02-15 Chugai Seiyaku K.K. Vaskularisierungsinhibitoren
EP2308996A1 (en) * 1998-03-30 2011-04-13 NorthWest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
WO2002000233A2 (en) * 2000-06-26 2002-01-03 Wellstat Biologics Corporation Purging of cells using viruses
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US20060019917A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
ATE347695T1 (de) 2001-06-07 2006-12-15 Chemocentryx Inc Zellwanderungsassay
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
EP1438321B1 (de) 2001-10-26 2010-05-26 Noxxon Pharma AG Modifizierte l-nukleinsäure
WO2003070823A2 (en) 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
EP1608318A4 (en) * 2003-03-27 2009-07-29 Univ Emory CXCR4 ANTAGONISTS AND METHOD OF USE
AU2004230927B9 (en) 2003-04-13 2011-12-01 Enzon Pharmaceuticals, Inc. Polymeric oligonucleotide prodrugs
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
EP1807092B1 (en) 2004-11-05 2016-09-07 The Children's Hospital of Philadelphia Biodegradable linkers for molecular therapies
WO2006126209A1 (en) * 2005-05-26 2006-11-30 Rappaport Family Institute For Research In The Medical Sciences Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions
US20070043012A1 (en) * 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
JP5244785B2 (ja) * 2006-08-11 2013-07-24 小野薬品工業株式会社 ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体
WO2008034122A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
AU2007337983A1 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (CCL2, CCL3, CCL5, CXCL11, CXCL12) single-domain antibodies
SG188220A1 (en) * 2010-09-09 2013-04-30 Noxxon Pharma Ag Sdf-1 binding nucleic acids and the use thereof in cancer treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008009437A2 (en) * 2006-07-18 2008-01-24 Noxxon Pharma Ag Sdf-i binding nucleic acids
WO2009019007A2 (en) * 2007-08-06 2009-02-12 Noxxon Pharma Ag Sdf-1 binding nucleic acids and the use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AZAB ABDEL KAREEM ET AL, BLOOD, 30 APR 2009, VOL 113, NO 18, PAGES 4341-4351 *
MEIKE BURGER ET AL, BLOOD, VOL 106, NO 5, 1 SEP 2005, PAGES 1824-1830 *

Also Published As

Publication number Publication date
US20130310442A1 (en) 2013-11-21
CA2810950C (en) 2023-02-14
CN103108641B (zh) 2016-01-13
MX357770B (es) 2018-07-24
US9387221B2 (en) 2016-07-12
SG10201506725QA (en) 2015-10-29
BR112013005664B1 (pt) 2021-11-03
EP2613789B1 (en) 2018-04-18
HK1184699A1 (zh) 2014-01-30
JP2013540725A (ja) 2013-11-07
KR101937939B1 (ko) 2019-01-11
US20160095875A1 (en) 2016-04-07
EP2613789A1 (en) 2013-07-17
DK2613789T3 (en) 2018-07-23
RU2013115739A (ru) 2014-10-20
RU2679495C2 (ru) 2019-02-11
CA2810950A1 (en) 2012-03-15
SG188220A1 (en) 2013-04-30
MX2013002722A (es) 2013-06-28
AU2011300818A1 (en) 2013-03-07
BR112013005664B8 (pt) 2023-04-25
KR20130114094A (ko) 2013-10-16
BR112013005664A2 (pt) 2020-08-04
US20160355821A1 (en) 2016-12-08
ES2678497T3 (es) 2018-08-13
US10093934B2 (en) 2018-10-09
WO2012031773A1 (en) 2012-03-15
JP6243736B2 (ja) 2017-12-06
CN103108641A (zh) 2013-05-15

Similar Documents

Publication Publication Date Title
JP5798549B2 (ja) ヘプシジン結合核酸
AU2008285939B2 (en) SDF-1 binding nucleic acids and the use thereof
KR101561652B1 (ko) Sdf-1 결합형 c형 핵산분자
US20210023116A1 (en) Treatment of cancer by systemic administration of dbait molecules
Sarli et al. Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo
US10093934B2 (en) SDF-1 binding nucleic acids and the use thereof in cancer treatment
US20230146246A1 (en) Method of Modulating the Number and the Distribution of Tumor-Infiltrating Leukocytes in Tumors
HK1184699B (en) Sdf-1 binding nucleic acids and the use thereof in cancer treatment
Lourenço et al. Therapeutic Applications of Nucleic Acid Aptamers
HK1144956B (en) Sdf-1 binding nucleic acids and the use thereof
AU2013200034A1 (en) Sdf-i binding nucleic acids

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: TME PHARMA AG

Free format text: FORMER NAME(S): NOXXON PHARMA AG